title: Acute and chronic effects of biliopancreatic diversion with duodenal switch surgery on plasma visfatin and apelin levels in patients with severe obesity.
abstract: BACKGROUND
  Visfatin is an adipokine linked to obesity and inflammation, and it has insulin-mimetic properties. Apelin is an adipokine with positive cardiac inotropic effects, and it may be related to inflammatory molecules. Variations in plasma visfatin and apelin levels following bariatric surgery remain controversial.
  
  
  METHODS
  In this study, patients who underwent a biliopancreatic diversion with duodenal switch (BPD-DS) were compared to a severely obese group (control group). Anthropometric measures and blood samples were taken before surgery, on days 1 and 5, as well as at 6 and 12 months after surgery in the BDP-DS group. For the control group, the tests were performed at baseline and at 6 and 12 months.
  
  
  RESULTS
  Seventy subjects in the BPD-DS group and 28 in the control group were included. The expected reduction in body weight at 1 year after a BPD-DS was observed (85.9 ± 18.5 vs. 136.6 ± 27.7 kg at baseline; p < 0.001). Plasma visfatin levels decreased at day 1 (16.13 ± 5.56 vs. 18.82 ± 7.36 ng/mL at baseline; p = 0.001), while plasma apelin levels decreased at day 5 (0.50 ± 0.28 vs. 0.55 ± 0.33 ng/mL at baseline; p = 0.040) after surgery. There were no changes at 6 and 12 months compared to baseline, and no changes were observed in the control group.
  
  
  CONCLUSIONS
  Our data show that 1-year weight loss induced by BPD-DS did not influence the overall plasma visfatin and apelin levels in severely obese patients.
authors.affiliation: Institut universitaire de cardiologie et de pneumologie de Québec, 2725 Chemin Sainte-Foy, Quebec City, QC, Canada, G1V 4G5.
authors.forename: Sarah-Maude
authors.initials: SM
authors.lastname: Caron-Cantin
authors.forename: Julie
authors.initials: J
authors.lastname: Martin
authors.forename: Marjorie
authors.initials: M
authors.lastname: Bastien
authors.forename: Mercedes Nancy
authors.initials: MN
authors.lastname: Munkonda
authors.forename: Huiling
authors.initials: H
authors.lastname: Lu
authors.forename: Katherine
authors.initials: K
authors.lastname: Cianflone
authors.forename: Fady
authors.initials: F
authors.lastname: Moustarah
authors.forename: Laurent
authors.initials: L
authors.lastname: Biertho
authors.forename: Simon
authors.initials: S
authors.lastname: Marceau
authors.forename: Frédéric-Simon
authors.initials: FS
authors.lastname: Hould
authors.forename: Jean
authors.initials: J
authors.lastname: Bussières
authors.forename: Paul
authors.initials: P
authors.lastname: Poirier
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism* / Q000601:surgery; D000328:Adult; D000073861:Apelin; D001055:Apolipoproteins B / Q000378:metabolism; D015904:Biliopancreatic Diversion; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism; D016207:Cytokines / Q000097:blood*; D004386:Duodenum / Q000601:surgery*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000453:epidemiology / Q000378:metabolism; D007333:Insulin Resistance; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D008297:Male; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D009767:Obesity, Morbid / Q000097:blood / Q000453:epidemiology / Q000601:surgery*; D011792:Quebec / Q000453:epidemiology; D016896:Treatment Outcome; D015431:Weight Loss
chemical_list: D000073861:Apelin; D001055:Apolipoproteins B; D002097:C-Reactive Protein; D008078:Cholesterol, LDL; D016207:Cytokines; D006442:Glycated Hemoglobin; D036341:Intercellular Signaling Peptides and Proteins; D054409:Nicotinamide Phosphoribosyltransferase; C115436:APLN protein, human; C517652:hemoglobin A1c protein, human; C085455:nicotinamide phosphoribosyltransferase, human